New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
16:16 EDTGHDXGenomic Health sees FY13 EPS ex-items 48c-68c, consensus 28c
Sees FY13 revenue $258M-$266M, consensus $262.4M. The company said, "In 2013, we plan to continue to invest in near-term opportunities to expand our global breast and colon cancer businesses in order to drive top-line revenue growth, and in our prostate cancer launch to build long-term value, and expect losses in the first and second quarters." Sees FY13 GAAP EPS (12c)-8c and non-GAAP basic EPS, excluding stock compensation expense, 48c-68c.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
08:10 EDTGHDXGenomic Health's Oncotype prostate cancer shows positive results
Genomic Health announced positive published results from the first decision impact study of the Oncotype DX prostate cancer test showing that use of the test substantially increased the number of men who can consider active surveillance, while increasing physician confidence in their treatment recommendations. This prospective study showed that incorporation of the Genomic Prostate Score changed modality and/or intensity of treatment recommendations in 26% of patients across multiple urology practice settings. Additionally, 85% of urologists were more confident in their treatment recommendation following review of the GPS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use